Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00964093 · ClinicalTrials.gov registry record · NA

The Effectiveness of Silver Alginate (Algidex) Patch in the Prevention of Central Line Infections in Very Low Birth Weight Infants

A NA study of Central Line Bloodstream Infections, sponsored by Baylor Research Institute.

Completed
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT00964093: Completed NA study of Central Line Bloodstream Infections, sponsored by Baylor Research Institute.

NCT00964093 is a NA study of Central Line Bloodstream Infections that has completed, run by Baylor Research Institute. The registered enrollment target is 100 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00964093, a NA study of Central Line Bloodstream Infections, has completed, sponsored by Baylor Research Institute.

COMPLETED
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether silver alginate (Algidex) patch is effective in the prevention of central line infections in very low birth weight infants.

Interventions

  • DEVICE Silver Alginate

Study Locations (1)

Texas

  • Baylor University Medical Center - Women and Children's Services - Dallas

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2008-11-23
Est. Completion 2015-08-20
Phase NA
Baylor Research Institute

180 total trials

What the finished NCT00964093 record still lists

NCT00964093 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Central Line Bloodstream Infections appearing as the primary indexed condition, and to 1 intervention - of which Silver Alginate is the first listed.

NCT00964093 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00964093 about?

NCT00964093 is a clinical study titled "The Effectiveness of Silver Alginate (Algidex) Patch in the Prevention of Central Line Infections in Very Low Birth Weight Infants". The purpose of this study is to determine whether silver alginate (Algidex) patch is effective in the prevention of central line infections in very low birth weight infants.

What is the current status of trial NCT00964093?

This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2008-11-23. Estimated completion is 2015-08-20.

What conditions does trial NCT00964093 study?

This clinical trial studies the following conditions: Central Line Bloodstream Infections.

What interventions are being tested in trial NCT00964093?

The interventions under investigation include: Silver Alginate (DEVICE).

Who is sponsoring clinical trial NCT00964093?

This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00964093 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT00964093's enrollment target sits among peer trials

100 840th of 2000 higher than 1,081 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00964093, the US trial registry maintained by the National Library of Medicine. NCT00964093 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.